{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:48:22Z","timestamp":1760384902729},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.3816\/clm.2007.s.008","type":"journal-article","created":{"date-parts":[[2008,9,16]],"date-time":"2008-09-16T01:34:44Z","timestamp":1221528884000},"page":"S95-S101","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S3","title":["Optimal Management of Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia in 2007"],"prefix":"10.3816","volume":"7","author":[{"given":"Tariq","family":"Mughal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2007.s.008_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.3816\/CLM.2007.s.008_bib2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of the BCR-ABL positive cells","volume":"2","author":"Druker","year":"2000","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.008_bib4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.008_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2741\/1792","article-title":"Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era","volume":"1","author":"Mughal","year":"2006","journal-title":"Front Biosci"},{"key":"10.3816\/CLM.2007.s.008_bib6","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.008_bib7","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-\u03b1 based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.2001.03155.x","article-title":"The probability of long-term leukaemia free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukaemia in chronic phase","volume":"115","author":"Mughal","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2007.s.008_bib9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromsome positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.008_bib10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant Philadelphia chromsome-positive leukemias","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.008_bib11","doi-asserted-by":"crossref","first-page":"611a","DOI":"10.1182\/blood.V108.11.2154.2154","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission: an update follow up","volume":"108","author":"Mahon","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib12","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2006.24.18_suppl.6535","article-title":"High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5 year follow-up","volume":"24","author":"Aoki","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.008_bib13","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(02)08616-6","article-title":"Cerebral edema as a possible complication of treatment with imatinib","volume":"359","author":"Ebonether","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLM.2007.s.008_bib14","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMcibr065325","article-title":"Another look at imatinib mesylate","volume":"355","author":"Strebhardt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2007.s.008_bib15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatib mesylate","volume":"12","author":"Kerakela","year":"2006","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.008_bib16","first-page":"224","article-title":"In reply to \u201ccardiotoxicity of the cancer therapeutic agent imatinib mesylate.\u201d","volume":"2","author":"Attallah","year":"2007","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.008_bib17","first-page":"224","article-title":"In reply to \u2018cardiotoxicity of the cancer therapeutic agent imatib mesylate.\u2019","volume":"2","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.008_bib18","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","article-title":"Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia","volume":"108","author":"Kovitz","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib19","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(02)07671-7","article-title":"Resistance to targeted therapy in leukaemia","volume":"359","author":"Griffin","year":"2002","journal-title":"Lancet"},{"key":"10.3816\/CLM.2007.s.008_bib20","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib21","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2005-07-2625","article-title":"Mutation detection in CML: is it a useful tool?","volume":"106","author":"Guilhot","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors \u2013 recommendations for \u2018harmonizing\u2019 current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib24","doi-asserted-by":"crossref","first-page":"6316","DOI":"10.1200\/JCO.2005.05.009","article-title":"New targeted approaches in chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.008_bib25","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib26","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.008_bib27","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib28","first-page":"288a","article-title":"Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (pts) with chronic myeloid leukemia (CML) after failure to imatinib","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib29","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3816\/CLK.2006.n.003","article-title":"Dasatinib, a novel Abl-Src kinase inhibitor, in the management of patients with Philadelphia chromosome-positive leukemias","volume":"1","author":"Mughal","year":"2006","journal-title":"Clin Leuk"},{"key":"10.3816\/CLM.2007.s.008_bib31","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib32","doi-asserted-by":"crossref","first-page":"53a","DOI":"10.1182\/blood.V108.11.164.164","article-title":"Efficacy of dasatinib (Sprycel) in patients with chronic phase chronic myeloid leukaemia resistant to or intolerant of imatinib: updated results of CA180013 \u201cSTART-C\u201d phase II study","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib33","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.2161.2161","article-title":"Dasatinib (Sprycel) in patients with previously untreated chronic myelogenous leukaemia in chronic phase","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib34","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukaemia after failure of imatinib therapy","author":"Hochhaus","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib35","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chrnic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Qunitas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib36","first-page":"53a","article-title":"Dasatinib (Sprycel) 50mg or 70mg BID versus 110mg or 140mg QD in patients with chronic myeloid leukemia in chronic phase resistant or intolerant to imatinib : results of the CA180-034 study","volume":"108","author":"Hocchaus","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib37","doi-asserted-by":"crossref","first-page":"613a","DOI":"10.1182\/blood.V108.11.2161.2161","article-title":"Dasatinib (Srycel) in patients with previously untreated chronic myeloid leukemia in chronic phase","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3816\/CLK.2006.n.012","article-title":"Nilotinib in the post-imatinib era for the treatment of Philadelphia chromosome positive leukemias","volume":"1","author":"Mughal","year":"2006","journal-title":"Clin Leuk"},{"issue":"18 suppl","key":"10.3816\/CLM.2007.s.008_bib40","first-page":"358s","article-title":"Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome(Ph)-positive chronic phase chronic myelogenous leukemia","volume":"24","author":"Jabbour","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2007.s.008_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/80795","article-title":"Immunotherapy of human cancer: lessons from mice","volume":"1","author":"Srivastava","year":"2000","journal-title":"Nat Immunol"},{"issue":"suppl","key":"10.3816\/CLM.2007.s.008_bib42","first-page":"177","article-title":"The immune response to BCR-ABL peptide immunization is variable and transient in chronic myeloid leukaemia: results from the EPIC study","volume":"1","author":"Rojas","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2007.s.008_bib43","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.3816\/CLM.2007.s.008_bib44","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLM.2007.s.008_bib45","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2004-05-1915","article-title":"Induction of BCR-ABL-specific immunity following vaccination with chaperone rich lysates from BCR-ABL+ tumor cells","volume":"105","author":"Zeng","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib46","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WTI (Wilms tumor gene)-specific cytotoxic T lymphocytes by WTI peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2007.s.008_bib47","doi-asserted-by":"crossref","first-page":"54a","DOI":"10.1182\/blood.V108.11.168.168","article-title":"A phase1\/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL) relapsed, refractory or intolerant of imatinib","volume":"108","author":"Cortes","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib48","doi-asserted-by":"crossref","first-page":"618a","DOI":"10.1182\/blood.V108.11.2179.2179","article-title":"The ATP competitor INNO-406 (NS-187) inhibits proliferation and survival of mouse cells expressing several imatinib mesylate resistant Bcr\/Abl mutants and cells from CML patients","volume":"108","author":"Tao","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib49","doi-asserted-by":"crossref","first-page":"80a","DOI":"10.1182\/blood.V108.11.257.257","article-title":"Inhibition of histone deactylase (HDAC) 6 and\/or heat shock protein (HSP) 90: a strategy to abrogate multi-level protective responses to misfolded proteins induced by proteasome inhibitors in human leukemia cells","volume":"108","author":"Rao","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib50","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood-2004-09-3534","article-title":"PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myelogenous leukemia","volume":"105","author":"Wolff","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib51","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib52","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of surviving expression through Bcr-Abl\/MAPK cascade: targeting surviving overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2007.s.008_bib53","first-page":"452","article-title":"The effects of prior exposure to imatinib on transplant related mortality","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2007.s.008_bib54","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011701226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T08:38:21Z","timestamp":1588927101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011701226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":54,"alternative-id":["S1557919011701226"],"URL":"https:\/\/doi.org\/10.3816\/clm.2007.s.008","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}